Notably, CNS-derived EVs from AD patients have been shown to be highly potent in inducing tau spreading in vivo: when injected into the mouse brain, tau-loaded EVs triggered widespread tau pathology in recipient neurons, predominantly in hippocampal GABAergic interneurons, whereas equivalent amounts of free tau oligomers or fibrils caused minimal effect [49]. The gene discussed is MAPT; the disease is Alzheimer disease.